Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.37 |
| ▸ | KIF11 | P52732 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | FYN | P06241 | 1/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
| ▸ | FLT1 | P17948 | 1/20 | 0.35 |
| ▸ | GRK5 | P34947 | 1/20 | 0.35 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
| ▸ | CDK8 | P49336 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7749391 | 0.93 | MIF (0.37) | TSHRALDH1A1ESR1CYP3A4ESR2 | |
| SCHEMBL7953170 | 0.92 | KIF11 (0.35) | TSHRALDH1A1ESR1CYP3A4ESR2 | |
| SCHEMBL6139488 | 0.92 | KIF11 (0.35) | TSHRALDH1A1ESR1CYP3A4ESR2 | |
| SCHEMBL7749385 | 0.91 | KIF11 (0.38) | TSHRFFAR1KIF11CYP2C19CASP1 | |
| SCHEMBL7077078 | 0.91 | SLC6A2 (0.32) | TSHRALDH1A1ESR1CYP3A4ESR2 | |
| SCHEMBL7957554 | 0.91 | SLC6A2 (0.32) | TSHRALDH1A1ESR1CYP3A4ESR2 | |
| SCHEMBL6544463 | 0.90 | L3MBTL1 (0.41) | TSHRALDH1A1ESR1CYP3A4ESR2 | |
| SCHEMBL6955463 | 0.89 | ALDH1A1 (0.35) | TSHRALDH1A1ESR1CYP3A4ESR2 | |
| SCHEMBL7137116 | 0.89 | ALDH1A1 (0.35) | TSHRALDH1A1ESR1CYP3A4ESR2 | |
| SCHEMBL7750624 | 0.88 | SMN1; SMN2 (0.36) | TSHRALDH1A1ESR1CYP3A4ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0888304-B1 | SUBSTITUTED 3-ARYL-3-CARBOXYALKYL GLUTARAMIDES, METHOD FOR PREPARING SAME BY 4-ARYLO-4-CYANOHEPTANE DICARBOXYLIC ACID CYCLISATION, AND USE THEREOF FOR PREPARING 3-ARYL-3-HYDROXYALKYLPIPERIDINES | SANOFI SYNTHELABO (FR) | 2001-10-04 | — | — | EP | claimed |
| EP-0888304-A1 | SUBSTITUTED 3-ARYL-3-CARBOXYALKYL GLUTARAMIDES, METHOD FOR PREPARING SAME BY 4-ARYLO-4-CYANOHEPTANE DICARBOXYLIC ACID CYCLISATION, AND USE THEREOF FOR PREPARING 3-ARYL-3-HYDROXYALKYLPIPERIDINES | SANOFI (FR) | 1999-01-07 | — | — | EP | claimed |
| WO-1997032852-A1 | SUBSTITUTED 3-ARYL-3-CARBOXYALKYL GLUTARAMIDES, METHOD FOR PREPARING SAME BY 4-ARYLO-4-CYANOHEPTANE DICARBOXYLIC ACID CYCLISATION, AND USE THEREOF FOR PREPARING 3-ARYL-3-HYDROXYALKYLPIPERIDINES | SANOFI (FR) | 1997-09-12 | — | — | WO | claimed |
| WO-2023278843-A2 | SOLID FORMS OF OSANETANT | ACER THERAPEUTICS, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
| US-6946269-B2 | Alkyl esters of 3-(3,4-dihalophenyl)-2,6-dioxopiperidine-3-propionic acid of use as intermediates | SANOFI-AVENTIS (FR) | 2005-09-20 | — | — | US | disclosed |
| US-20040110796-A1 | Alkyl esters of 3- (3,4-dihalophenyl) -2, 6 -di -oxopiperidine-3 -propionic acid of use as intermediates | SANOFI-AVENTIS (FR) | 2004-06-10 | — | — | US | disclosed |
| US-6686182-B2 | ANTAGONISTS OF NATURAL KILLER CELL-3 RECEPTORS | SANOFI-SYNTHELABO (FR) | 2004-02-03 | — | — | US | disclosed |
| EP-1019373-B1 | 1-ACYL-3-PHENYL-3-(3-PIPERIDINOPROPYL)PIPERIDINE DERIVATIVES AS HUMAN NK3 RECEPTOR SELECTIVE ANTAGONISTS | SANOFI SYNTHELABO (FR) | 2003-11-12 | — | — | EP | disclosed |
| US-20030032810-A1 | Alkyl esters of 3- (3,4-dihalophenyl) -2,6-dioxopoperidine-3-propionic acid of use as intermediates | SANOFI-AVENTIS (FR) | 2003-02-13 | — | — | US | disclosed |
| US-6469173-B1 | AN INTERMEDIATE OF USE IN THE PREPARATION OF OSANETANT. OSANETANT IS A SPECIFIC ANTAGONIST OF NK3 RECEPTORS | SANOFI-SYNTHELABO (FR) | 2002-10-22 | — | — | US | disclosed |
| EP-1241168-A1 | Human NK3 receptor-selective antagonist compounds, process for their obtention and pharmaceutical compositons containing them | SANOFI-SYNTHELABO (FR) | 2002-09-18 | — | — | EP | disclosed |
| EP-1019373-A1 | NOVEL HUMAN NK 3? RECEPTOR-SELECTIVE ANTAGONIST COMPOUNDS, METHOD FOR OBTAINING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI-SYNTHELABO (FR) | 2000-07-19 | — | — | EP | disclosed |
| US-6008360-A | Substituted 3-aryl-3-carboxyalkyl glutaramides, method for preparing same by 4-arylo-4-cyanoheptane dicarboxylic acid cyclisation, and use thereof for preparing 3-aryl-3-hydroxyalkylpiperidines | SANOFI-SYNTHELABO (FR) | 1999-12-28 | — | — | US | disclosed |
| EP-0888304-A1 | SUBSTITUTED 3-ARYL-3-CARBOXYALKYL GLUTARAMIDES, METHOD FOR PREPARING SAME BY 4-ARYLO-4-CYANOHEPTANE DICARBOXYLIC ACID CYCLISATION, AND USE THEREOF FOR PREPARING 3-ARYL-3-HYDROXYALKYLPIPERIDINES | SANOFI (FR) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997032852-A1 | SUBSTITUTED 3-ARYL-3-CARBOXYALKYL GLUTARAMIDES, METHOD FOR PREPARING SAME BY 4-ARYLO-4-CYANOHEPTANE DICARBOXYLIC ACID CYCLISATION, AND USE THEREOF FOR PREPARING 3-ARYL-3-HYDROXYALKYLPIPERIDINES | SANOFI (FR) | 1997-09-12 | — | — | WO | disclosed |
| WO-1997010211-A1 | NOVEL HUMAN NK3 RECEPTOR-SELECTIVE ANTAGONIST COMPOUNDS, METHOD FOR OBTAINING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI (FR) | 1997-03-20 | — | — | WO | disclosed |
| EP-0673928-A1 | Novel N-(3,4-dichlorophenyl-propyl)-piperidine derivatives as selective human NK3-receptor antagonists | SANOFI (FR) | 1995-09-27 | — | — | EP | disclosed |
| US-4460604-A | ANALGESICS, NARCOTIC ANTAGONIST | THE UPJOHN COMPANY (US) | 1984-07-17 | — | — | US | disclosed |
| US-4180584-A | ANALGESIC; NARCOTIC ANTAGONIST | THE UPJOHN COMPANY (US) | 1979-12-25 | — | — | US | disclosed |
| US-4065573-A | ANALGESICS | THE UPJOHN COMPANY (US) | 1977-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030032810-A1 | Alkyl esters of 3- (3,4-dihalophenyl) -2,6-dioxopoperidine-3-propionic acid of use as intermediates | PCCA, NAPEPLD, DECR2 | TSHR 2057/4885ALDH1A1 105/4885ESR1 2753/4885 |
| US-20040110796-A1 | Alkyl esters of 3- (3,4-dihalophenyl) -2, 6 -di -oxopiperidine-3 -propionic acid of use as intermediates | NAPEPLD, FFAR3, APEH | TSHR 1879/4885ALDH1A1 307/4885ESR1 2485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.